Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ChAd3-hliNSmut · 1 trial · 1 indication
To evaluate the safety of administering HCV prime-boost vaccinations, ChAd3-hliNSmut and MVA-hilNSmut intramuscularly in healthy volunteers and DAA treated volunteers that were previously infected with HCV
| Arm | Type | Description |
|---|---|---|
| Group 1 (low dose/healthy volunteers) | EXPERIMENTAL | 5 healthy volunteers receiving 1 dose ChAd3-hliNSmut (5x10\*9 vp) IM at week 0 and 1 dose of MVA-hliNSmut (5 X10\*7 pfu) IM at week 8 |
| Group 2 (higher dose/healthy volunteers) | EXPERIMENTAL | 10 healthy volunteers receiving 1 dose ChAd3-hliNSmut (2.5 x10\*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X 10\*8 pfu) IM at week 8 |
| Group 3 (higher dose/HCV cured volunteers) | EXPERIMENTAL | 10 DAA treated volunteers (previously HCV positive) receiving 1 dose ChAd3-hliNSmut (2.5 x10\*10 vp) IM at week 0 and 1 dose of MVA-hliNSmut (2 X10\*8 pfu) IM at week 8 |
| Name | Type | Description |
|---|---|---|
| ChAd3-hliNSmut | BIOLOGICAL | Attenuated chimpanzee adenovirus (ChAd) vectored vaccine against HCV |
| MVA-hliNSmut | BIOLOGICAL | Modified Vaccinia Ankara (MVA) vectored vaccine against HCV |
Inclusion Criteria: * Aged at least 18 years on the day of screening and no greater than 65 years on the day of the first vaccination * Resident in or easy access to the trial site for the duration of the study * Available for follow-up for the planned duration of the study * Able and willing (in t...
Top 1 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Atea Pharmaceuticals, Inc. | AVIR | 2 | PHASE3 | Bemnifosbuvir-Ruzasvir |
ChAd3-hliNSmut is an investigational vaccine candidate being developed by GSK plc for hepatitis C. It is designed to stimulate an immune response against the hepatitis C virus. It has been studied in a single Phase 1 clinical trial that has completed enrollment of 25 participants.
ChAd3-hliNSmut is being developed for the prevention or treatment of hepatitis C virus infection. It is not yet approved for any use and remains an investigational product. The only clinical trial of this candidate enrolled participants with hepatitis C or healthy volunteers.
ChAd3-hliNSmut is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the clinical program for this hepatitis C vaccine candidate.
ChAd3-hliNSmut is in Phase 1 clinical development. It has not been approved by the FDA or any other regulatory agency. The Phase 1 trial has been completed, and no active trials are currently listed for this candidate.
ChAd3-hliNSmut has been studied in one clinical trial: NCT03688061, titled "Class II Invariant Chain HCV Vaccine Study." This Phase 1 trial was conducted in the United Kingdom, enrolled 25 participants, and has been completed. It included healthy volunteers and was a controlled study.